Please assess the completion status of the following clinical trial:

Trial Title: DNP-Modified Autologous Tumor Cell Vaccine for Resectable Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically documented stage IA, IB, IIA, IIB or IIIA NSCLC that is completely resectable and does not require post-operative radiation therapy or peri-operative chemotherapy~* Excision of the tumor and harvesting of tumor mass yielding adequate cells for vaccine manufacture and DTH testing~* Successful preparation and lot release of vaccines and of DTH testing material containing DNP-modified tumor cells~* Minimum of 3 and maximum of 8 weeks since the surgery~* Expected survival of at least 6 months~* Karnofsky performance status ³ 80~* Signed informed consent~Exclusion Criteria:~Alkaline phosphatase \> 2.5 x ULN~* Total bilirubin \> 2.0 mg/dL~* Creatinine \> 2.0 mg/dL~* Hemoglobin \< 10.0 g/dL~* WBC \< 3,000 /mm3~* Platelet count \< 100,000/mm3~* Chemotherapy - pre-operative or post-operative (except as designated in protocol)~* Radiation therapy to lung - pre-operative or post-operative~* Any major field radiotherapy within 6 months prior to participation in the study~* Immunotherapy (interferons, tumor necrosis factor, other cytokines \[e.g., interleukins\], biological response modifiers, or monoclonal antibodies) within 4 weeks prior to participation in the study~* Prior splenectomy~* Concurrent use of systemic steroids, except for the period of administration of the adjuvant chemotherapy, as per Section 8.6 (months 4-7)(Note: Topical steroid therapies \[applied to the skin\] are allowed, provided these are not applied to limbs injected with vaccine or skin test materials. Inhaled aerosol steroids are allowed.)~* Concurrent use of immunosuppressive drugs, except for the period of administration of the adjuvant chemotherapy (months 4-7)~* Concurrent use of antitubercular drugs (isoniazid, rifampin, streptomycin)~* Other malignancy within 5 years except curatively treated non-melanomatous skin cancer and curatively treated carcinoma in situ of the uterine cervix, or early stage (stage A or B1) prostate cancer~* Concurrent autoimmune diseases, e.g., systemic lupus erythematosus, multiple sclerosis or ankylosing spondylitis~* Concurrent medical condition that would preclude compliance or immunologic response to study treatment~* Concurrent serious infection or other serious medical condition~* Receipt of any investigational medication within 4 weeks prior to participation in the study~* Pregnancy or lactation (serum b-human chorionic gonadotropin \[b-HCG\] test must be negative in fertile women at screening visit)~* Active tuberculosis or a past history of tuberculosis~* PPD positive (³ 5 mm to 5TU)~* Known gentamicin sensitivity~* Anergic, defined by the inability to make a DTH to at least one of the following: candida, mumps, tetanus or trichophyton (based, except for the period of administration of the adjuvant chemotherapy (months 4-7) upon availability)~* Vaccine lot release failure

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): 5 million autologous, DNP-modified NSCLC cells
- 2 (Type: EXPERIMENTAL): 2.5 million autologous, DNP-modified NSCLC cells
- 3 (Type: EXPERIMENTAL): 0.5 million autologous, DNP-modified NSCLC cells

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval